WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H575132
CAS#: 525-66-6 (free base)
Description: Propranolol is a non-selective beta receptor antagonist. It competes with sympathomimetic neurotransmitters for binding to receptors, which inhibits sympathetic stimulation of the heart. Blockage of neurotransmitter binding to β1 receptors on cardiac myocytes inhibits activation of adenylate cyclase, which in turn inhibits cAMP synthesis leading to reduced PKA (Protein Kinase A) activation. This results in less calcium influx to cardiac myocytes through voltage gated L-type calcium channels meaning there is a decreased sympathetic effect on cardiac cells, resulting in antihypertensive effects including reduced heart rate and lower arterial blood pressure Blockage of neurotransmitter binding to β2 receptors on smooth muscle cells will increase contraction, which will increase hypertension.
Hodoodo Cat#: H575132
Name: Propranolol free base
CAS#: 525-66-6 (free base)
Chemical Formula: C16H21NO2
Exact Mass: 259.16
Molecular Weight: 259.350
Elemental Analysis: C, 74.10; H, 8.16; N, 5.40; O, 12.34
Related CAS #: 318-98-9 (HCl) 525-66-6 (free base)
Synonym: Anapriline; Avlocardyl; AY 20694; AY20694; AY-20694; beta-Propranolol; Betadren; Corpendol; Propranolol
IUPAC/Chemical Name: 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
InChi Key: AQHHHDLHHXJYJD-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
SMILES Code: CC(C)NCC(O)COc1cccc2ccccc12
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 259.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Shafique MA, Haseeb A, Uddin MMN, Asghar B, Chaudhry ER, Raqib MA, Ali SMS, Mustafa MS. Effectiveness of Propranolol in Preventing Severe Retinopathy of Prematurity: A Comprehensive Systematic Review and Meta-Analysis. Am J Ophthalmol. 2023 Nov 17;259:141-150. doi: 10.1016/j.ajo.2023.11.012. Epub ahead of print. PMID: 37979602.
2: Ikramuddin S, Liu S, Ryan D, Hassani S, Hasan D, Feng W. Propranolol or Beta- Blockers for Cerebral Cavernous Malformation: a Systematic Review and Meta- analysis of Literature in Both Preclinical and Clinical Studies. Transl Stroke Res. 2023 Oct 19. doi: 10.1007/s12975-023-01199-5. Epub ahead of print. PMID: 37857790.
3: Afifi S, Suryadevara V, Habab Y, Hutcheson A, Panjiyar BK, Davydov GG, Nashat H, Ghali S, Khan S. Comparing the Incidence of Propranolol and Esmolol-Related Cardiac Arrest in Patients With Thyroid Storm: A Systematic Literature Review. Cureus. 2023 Sep 4;15(9):e44655. doi: 10.7759/cureus.44655. PMID: 37799246; PMCID: PMC10549781.
4: İlhan ÇF, Kışlal S. Memory Impairing Effect of Propranolol on Consolidation and Reconsolidation for Various Learning Tasks. Noro Psikiyatr Ars. 2023 Aug 3;60(3):271-282. doi: 10.29399/npa.28203. PMID: 37645086; PMCID: PMC10461772.
5: Dardari L, Taha M, Dahat P, Toriola S, Satnarine T, Zohara Z, Adelekun A, Seffah KD, Salib K, Arcia Franchini AP. The Efficacy of Carvedilol in Comparison to Propranolol in Reducing the Hepatic Venous Pressure Gradient and Decreasing the Risk of Variceal Bleeding in Adult Cirrhotic Patients: A Systematic Review. Cureus. 2023 Aug 10;15(8):e43253. doi: 10.7759/cureus.43253. PMID: 37577269; PMCID: PMC10416553.
6: Reinert JP, Kormanyos Z. Pharmacologic Management of Central Fever: A Review of Evidence for Bromocriptine, Propranolol, and Baclofen. J Pharm Technol. 2023 Feb;39(1):29-34. doi: 10.1177/87551225221132678. Epub 2022 Nov 3. PMID: 36755757; PMCID: PMC9899958.
7: Mortlock R, Smith V, Nesci I, Bertoldi A, Ho A, El Mekkawi Z, Kakuzada L, Williams K, Pont L, De Rubis G, Dua K. A comparative evaluation of propranolol pharmacokinetics in obese versus ideal weight individuals: A blueprint towards a personalised medicine. Chem Biol Interact. 2023 Feb 1;371:110351. doi: 10.1016/j.cbi.2023.110351. Epub 2023 Jan 12. PMID: 36640929.
8: Tampi RR, Tampi DJ, Farheen SA, Ochije SI, Joshi P. Propranolol for the management of behavioural and psychological symptoms of dementia. Drugs Context. 2022 Dec 8;11:2022-8-3. doi: 10.7573/dic.2022-8-3. PMID: 36544625; PMCID: PMC9753600.
9: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Propranolol. 2022 Nov 30. PMID: 30000221.
10: Szeleszczuk Ł, Frączkowski D. Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder. Int J Mol Sci. 2022 Sep 3;23(17):10099. doi: 10.3390/ijms231710099. PMID: 36077489; PMCID: PMC9456064.
11: Albiñana V, Gallardo-Vara E, Casado-Vela J, Recio-Poveda L, Botella LM, Cuesta AM. Propranolol: A "Pick and Roll" Team Player in Benign Tumors and Cancer Therapies. J Clin Med. 2022 Aug 4;11(15):4539. doi: 10.3390/jcm11154539. PMID: 35956154; PMCID: PMC9369479.
12: Ganeva K, Shivachev P, Sapundzhiev N, Nikiforova L. Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review. Folia Med (Plovdiv). 2021 Aug 31;63(4):601-607. doi: 10.3897/folmed.63.e58121. PMID: 35851161.
13: Tiefenbach J, Park JJ, Kaliaperumal C. A 5-year outcome of propranolol for the treatment of paediatric intracranial cavernoma: case report and a review of the literature. Childs Nerv Syst. 2023 Jan;39(1):269-272. doi: 10.1007/s00381-022-05603-7. Epub 2022 Jul 14. Erratum in: Childs Nerv Syst. 2022 Dec 13;: PMID: 35836010.
14: Chen T, Gudipudi R, Nguyen SA, Carroll W, Clemmens C. Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol. Ann Otol Rhinol Laryngol. 2023 Mar;132(3):332-340. doi: 10.1177/00034894221089758. Epub 2022 Apr 25. PMID: 35466712.
15: Cuesta AM, Gallardo-Vara E, Casado-Vela J, Recio-Poveda L, Botella LM, Albiñana V. The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases. Int J Mol Sci. 2022 Apr 11;23(8):4217. doi: 10.3390/ijms23084217. PMID: 35457036; PMCID: PMC9025921.
16: Boyraz RK, Şahan E, Kırpınar İ. A Case Report with a Mini-Review of the Literature on the Overeating and Weight Gain Due to Propranolol. Psychiatr Danub. 2021 Dec;33(Suppl 13):330-332. PMID: 35150504.
17: Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. Propranolol. 2022 Jan. PMID: 35952192.
18: Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. Propranolol. 2022 Jan. PMID: 35952191.
19: Tan X, Guo S, Wang C. Propranolol in the Treatment of Infantile Hemangiomas. Clin Cosmet Investig Dermatol. 2021 Sep 3;14:1155-1163. doi: 10.2147/CCID.S332625. PMID: 34511960; PMCID: PMC8423716.
20: Young C, Butcher R. Propranolol for Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Mar 18. PMID: 33074615.
